Bessor Pharma



Bessor’s Collaborators Publish Paper on Renalase Potential as Acute Pancreatitis Treatment

Bessor’s Collaborators Publish Study on Potential of Renalase as Acute Pancreatitis Treatment Gary Desir, MD, Fred Gorelick, MD and colleagues at Yale University reported in the Journal of Biological Chemistry that renalase reduces cell injury and the severity of acute pancreatitis in animal models.​ Read the study

Bessor Pharma Receives SBIR Grant for New Pancreatitis Treatment

BESSOR PHARMA RECEIVES $300,000 PHASE 1 SBIR GRANT TO DEVELOP NOVEL TREATMENT FOR PANCREATITIS Framingham, MA, November 22, 2016 - Bessor Pharma has received a $300,000 Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to develop a new therapeutic for acute pancreatitis, the ...READ MORE

An innovative technology/ business model for new drug development and value creation. With a top leadership team focused on translating opportunities from university labs into clinical ready and proof-of-concept packages for the pharma/biotech industry